Figures computed from official regulatory filings — .
Ownershipinsiders 21.01% · institutions 2.55%
In USD · as of Nov 9, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Sigyn Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Sigyn Therapeutics, Inc., a development-stage company, develops and sells medical devices to treat cancer and infectious disease disorders in the United States. Its lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging pandemic threats. The company is also involved in the evaluation of Sigyn therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the performance of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.
Market information source · Nov 9, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Nov 9, 2026
Purchases and sales · full history
5 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Segelman Josephtrack record | Buy | $680 | conv 53Unusual size | SEC | |
| Segelman Josephtrack record | Buy | $1.5K | conv 61Unusual size | SEC | |
| Segelman Josephtrack record | Buy | $300 | conv 30 | SEC | |
| Segelman Josephtrack record | Buy | $500 | conv 43 | SEC | |
| Segelman Josephtrack record | Buy | $500 | conv 52First in 12mo | SEC |